Advertisement

Phytothérapie

, 9:113 | Cite as

Probiotiques et maladies inflammatoires cryptogénétiques de l’intestin

  • P. Marteau
  • M. Camus
Formation Continue Phytothérapie Clinique
  • 171 Downloads

Résumé

Les probiotiques font l’objet de recherches actives dans les maladies inflammatoires chroniques de l’intestin. Un niveau de preuve satisfaisant d’efficacité ne peut être obtenu qu’avec des essais randomisés contrôlés. L’Escherichia coli Nissle 1917 est efficace dans la prévention de rechute de la rectocolite hémorragique (RCH). Le produit VSL#3 est efficace pour diminuer le risque de pochite. Les études dans la maladie de Crohn (MC) sont à ce jour soit négatives, soit insuffisantes. Les nombreux produits commercialisés sans étude ne doivent pas être employés, mais dénoncés.

Mots clés

Probiotiques Maladies inflammatoires cryptogénétiques de l’intestin Traitement de la maladie de Crohn Traitement de la rectocolite hémorragique Traitement de la pochite 

Probiotics and inflammatory bowel disease

Abstract

Probiotics are actively investigated in inflammatory bowel disease. Evidence of efficacy can only be obtained by randomized controlled trials. Escherichia coli Nissle 1917 is effective to prevent recurrence of ulcerative colitis. VSL#3 reduces the risk of pouchitis. All studies performed until now in Crohn’s disease have been negative or insufficient. Many commercial products without studies and with misleading claims should be blamed.

Keywords

Probiotics Inflammatory bowel disease Crohn’s disease treatment Ulcerative colitis treatment Pouchtis treatment 

Références

  1. 1.
    Bibiloni R, Fedorak RN, Tannock GW, et al. (2005) VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100: 1539–1546PubMedCrossRefGoogle Scholar
  2. 2.
    Bousvaros A, Guandalini S, Baldassano RN, et al. (2005) A randomised, double blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 11: 833–839PubMedCrossRefGoogle Scholar
  3. 3.
    Chermesh I, Tamir A, Reshef R, et al. (2007) Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn’s Disease. Dig Dis Sci 52: 385–389PubMedCrossRefGoogle Scholar
  4. 4.
    Desreumaux P, Dewit O, Belaiche J, et al. (2009) Prevention of Crohn’s disease postsurgical recurrence with Lactobacilluscasei DN-114001 strain: an European multicentric double blind clinical trial. Gut 58(Suppl II): A616Google Scholar
  5. 5.
    Doherty G, Bennett G, Patil S, et al. (2009) Interventions for prevention of postoperative recurrence of Crohn’s disease. Cochrane Database Syst Rev 4: CD006873PubMedGoogle Scholar
  6. 6.
    FAO/WHO (2001) Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf
  7. 7.
    Gionchetti P, Rizzello F, Venturi A, et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double blind, placebo-controlled trial. Gastroenterology 119: 305–309PubMedCrossRefGoogle Scholar
  8. 8.
    Gionchetti P, Rizzello F, Helwig U, et al. (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double blind, placebo-controlled trial. Gastroenterology 124: 1202–1209PubMedCrossRefGoogle Scholar
  9. 9.
    Guslandi M, Mezzi G, Sorghi M, Testoni PA (2000) Saccharomycesboulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 45: 1462–1464PubMedCrossRefGoogle Scholar
  10. 10.
    Kato K, Mizuno S, Umesaki Y, et al. (2004) Randomised placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 20: 1133–1141PubMedCrossRefGoogle Scholar
  11. 11.
    Kruis W, Schutz E, Fric P, et al. (1997) Double blind comparison of an oral Escherichiacoli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11: 853–858PubMedCrossRefGoogle Scholar
  12. 12.
    Kruis W, Fric P, Pokrotnieks J, et al. (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichiacoli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617–1623PubMedCrossRefGoogle Scholar
  13. 13.
    Madsen K, Backer JL, Leddin D, et al. (2008) A randomised controlled trial of VSL#3 for the prevention of endoscopic recurrence following surgery for Crohn’s disease. Gastroenterology 134(Suppl): A361Google Scholar
  14. 14.
    Marteau P, Shanahan F (2003) Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol 17: 725–740PubMedCrossRefGoogle Scholar
  15. 15.
    Marteau P, Lemann M, Seksik P, et al. (2006) Ineffectiveness of Lactobacillusjohnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55: 842–847PubMedCrossRefGoogle Scholar
  16. 16.
    Melgar S, Shanahan F (2010) Inflammatory bowel disease — from mechanisms to treatment strategies. Autoimmunity 43: 463–477PubMedCrossRefGoogle Scholar
  17. 17.
    Mimura T, Rizzello F, Helwig U, et al. (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53: 108–114PubMedCrossRefGoogle Scholar
  18. 18.
    Prantera C, Scribano ML, Falasco G, et al. (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut 51: 405–409PubMedCrossRefGoogle Scholar
  19. 19.
    Pronio A, Montesani C, Butteroni C, et al. (2008) Probiotic administration in patients with ileal pouchanal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 14: 662–668PubMedCrossRefGoogle Scholar
  20. 20.
    Rembacken BJ, Snelling AM, Hawkey PM, et al. (1999) Non-pathogenic Escherichiacoli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635–639PubMedCrossRefGoogle Scholar
  21. 21.
    Shen B, Brzezinski A, Fazio VW, et al. (2005) Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 22: 721–728PubMedCrossRefGoogle Scholar
  22. 22.
    Sokol H, Pigneur B, Watterlot L, et al. (2008) Faecalibacteriumprausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105: 16731–16736PubMedCrossRefGoogle Scholar
  23. 23.
    Sood A, Midha V, Makharia GK, et al. (2009) The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7: 1202–1209PubMedCrossRefGoogle Scholar
  24. 24.
    Travis SP, Stange EF, Lémann M, et al. for the European Crohn’s and Colitis Organisation (ECCO) (2008) European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis 2: 24–62PubMedCrossRefGoogle Scholar
  25. 25.
    Tursi A, Brandimarte G, Giorgetti GM, et al. (2004) Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10: PI126–PI131PubMedGoogle Scholar
  26. 26.
    Tursi A, Brandimarte G, Papa A, et al. (2010) Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double blind, randomised, placebo-controlled study. Am J Gastroenterol 105: 2218–2227PubMedCrossRefGoogle Scholar
  27. 27.
    Van Gossum A, Dewit O, Louis E, et al. (2007) Multicenter randomised-controlled clinical trial of probiotics (Lactobacillusjohnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after ileocaecal resection. Inflamm Bowel Dis 13: 135–142PubMedCrossRefGoogle Scholar
  28. 28.
    Zocco MA, dal Verme LZ, Cremonini F, et al. (2006) Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23: 1567–1574PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag 2011

Authors and Affiliations

  1. 1.Université Denis-DiderotParis-VIIFrance
  2. 2.Laboratoire de biologie EA 3199CNAMParisFrance
  3. 3.Département médicochirurgical de pathologie digestivehôpital LariboisièreParis cedexFrance

Personalised recommendations